HSPA5 and neoplasm: At day 9 post‐tumor cell implantation, mice with established intracranial U87 tumors (Fig 4A) received a single intravenous dose (5 × 1010 TU) of either targeted RGD4C/AAVP‐Grp78‐HSVtk or non‐targeted/AAVP‐Grp78‐HSVtk.